Pilot Study of Etanercept in Patients With Refractory Juvenile Dermatomyositis

To evaluate the efficacy of etanercept in patients with juvenile dermatomyositis (DM) refractory to standard treatment.

[1]  H. Rockette,et al.  Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. , 2013, Arthritis and rheumatism.

[2]  R. Silverman,et al.  Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. , 2012, The Journal of pediatrics.

[3]  J. Jarvis,et al.  Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. , 2011, Archives of dermatology.

[4]  B. Feldman,et al.  Protocols for the initial treatment of moderately severe juvenile dermatomyositis: Results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference , 2010, Arthritis care & research.

[5]  E. Perea-Millá,et al.  Single-point acupuncture and physiotherapy for the treatment of painful shoulder: a multicentre randomized controlled trial. , 2008, Rheumatology.

[6]  P. Woo,et al.  Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. , 2008, Rheumatology.

[7]  M. Crow,et al.  A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies , 2008, Annals of the rheumatic diseases.

[8]  M. Covelli,et al.  Use of etanercept in the treatment of dermatomyositis: a case series. , 2006, The Journal of rheumatology.

[9]  L. Kagen,et al.  Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients , 2006, Annals of the rheumatic diseases.

[10]  M. Netea,et al.  Successful Treatment of Dermatomyositis and Polymyositis with Anti-Tumor-Necrosis-Factor-Alpha: Preliminary Observations , 2003, European Neurology.

[11]  R. Bode,et al.  Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. , 2003, Arthritis and rheumatism.

[12]  L. Pachman,et al.  Expression of TNFα by muscle fibers in biopsies from children with untreated juvenile dermatomyositis : Association with the TNFα-308A allele , 2001 .

[13]  S. Manna,et al.  IFN-α Suppresses Activation of Nuclear Transcription Factors NF-κB and Activator Protein 1 and Potentiates TNF-Induced Apoptosis1 , 2000, The Journal of Immunology.

[14]  M. Feldmann,et al.  Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. , 2000, Arthritis and rheumatism.

[15]  L. Pachman,et al.  TNFα-308A allele in juvenile dermatomyositis: Association with increased production of tumor necrosis factor α, disease duration, and pathologic calcifications , 2000 .

[16]  I. Lundberg.  The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies , 2000, Current rheumatology reports.

[17]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975, The New England journal of medicine.

[18]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975 .